SB-408124, >=98% (HPLC), solid

SB-408124, >=98% (HPLC), solid

Application

SB-408124 was used to block orexin A-mediated cardiovascular effects in rats. It was used to study block the increase of endogenous glucose production mediated by bicuculline in rats.

Biochem/physiol Actions

SB-408124 blocks the orexin type 1 receptor that stimulates the production of stress hormone in hypothalamus. It blocks orexin A-induced increase in arterial pressure and elevation of heart rate in rats. SB-408124 modulates phrenic nerve activity that is important in respiration.

SB 408124 is an OX1 orexin receptor antagonist.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573897 SB-408124, >=98% (HPLC), solid off-white 100 JTARFZSNUAGHRB-UHFFFAOYSA-N 1S/C19H18F2N4O/c1-11-8-17(15-9-12(20)10-16(21)18(15)22-11)24-19(26)23-13-4-6-14(7-5-13)25(2)3/h4-10H,1-3H3,(H2,22,23,24,26) SIGMA-ALDRICH solid ≥98% (HPLC)
£629.57 (exc VAT) per 25MG
-
+
3573898 SB-408124, >=98% (HPLC), solid off-white 100 JTARFZSNUAGHRB-UHFFFAOYSA-N 1S/C19H18F2N4O/c1-11-8-17(15-9-12(20)10-16(21)18(15)22-11)24-19(26)23-13-4-6-14(7-5-13)25(2)3/h4-10H,1-3H3,(H2,22,23,24,26) SIGMA-ALDRICH solid ≥98% (HPLC)
£254.89 (exc VAT) per 5MG
-
+